Form **8937**(December 2017)
Department of the Treasury

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

OMB No. 1545-0123

Internal Revenue Service			See separate instructions.		
Part I Reporting	Issuer				
1 Issuer's name		2 Issuer's employer identification number (EIN)			
FibroGen, Inc.		77-0357827			
3 Name of contact for add	ditional information	4 Telephor	ne No. of contact	5 Email address of contact	
David DeLucia		415-978-1200	ir@fibrogen.com		
6 Number and street (or F	P.O. box if mail is not	7 City, town, or post office, state, and ZIP code of contact			
350 Bay Street, Suite 100 #	# 6009	San Francisco, CA 94133			
8 Date of action		9 Class	sification and description		
6/16/25		1-for-25	reverse stock split Commo	on Shares	
10 CUSIP number 11 Serial number(s)		•	12 Ticker symbol	13 Account number(s)	
215720001	245720004		FOEN	N/A	
31572Q881 Part II Organization	N.A	h additiona	FGEN statements if needed S	N/A See back of form for additional questions.	
				ate against which shareholders' ownership is measured for	
•		• •		ansaction in which the company applied a 1-for-25	
reverse stock split of its co					
reverse stock split of its of	ommon shares. The	COSII Halli	ber changed from 31372QC	300 to 31372Q001	
share or as a percenta the Internal Revenue Code tax basis held in all the co	age of old basis ► <u>The.</u> No gain or loss we mad preferre	ne transactio yas recognize d stock that	n described in Line 14 qua ed by the shareholders as a was held immediately prior	urity in the hands of a U.S. taxpayer as an adjustment per alified as a reorganization pursuant to section 368(a) of a result of the transaction. Each shareholder's aggregate or to the reverse stock split became the aggregate tax	
basis in the new amount o	of common stock he	eld by such s	hareholders following the i	reverse stock split.	
	_		* *	ulation, such as the market values of securities and the	
FibroGen remains the sam	ne following the tran	nsaction desc	cribed in Line 14. Therefor	re, the overall tax basis held in the	
shares did not change; ho	wever, the stock sp	olit reallocate	d each shareholder's tax b	pasis attributable from 25 shares to 1 share of	
FibroGen common stock.					

Form 8937 (12-2017) Page **2**

Part I	Organizati	onal Action (continu	ed)		
			tion(s) and subsection(s) upon whic	h the tax treatment is bas	sed ►
	1 368(a)(1)(E) - reca				
Section	1 354 - exchanges o	of stock and securities	n certain reorganizations		
	1 358 - basis to dist	ributees			
Revenu	ie Ruling 72-57				
					<u> </u>
40 C	on any reculting loc	a ha raaagnizad? N. The		a laga famili C. fadamal in	
			shareholders did not recognize	a loss for U.S. rederal in	come tax purposes as a result
of the tr	ransaction describ	ed on Line 14.			
					_
19 Pr	rovide any other info	ormation necessary to im	plement the adjustment, such as th	e reportable tax vear > T	he adjustment to the tay basis
			year in which the transaction occu	_	
		is is applied in the tax y	year iii willcii the transaction occt	urreu. As sucri, lax basi	is in the shares is adjusted
in 2025.					
					_
	Under penalties of p	eriury I declare that I have	examined this return, including accompa	anving schedules and statem	nents, and to the best of my knowledge and
		ct, and complete. Declaration	on of preparer (other than officer) is based		
Sign		Signed by:			•
Here		David Delucia			7/30/2025
11616	Signature ►	1D2D8809CD42451		Date ▶	
		David DeLucia			SVP, Chief Financial Officer • Finance
	Print your name ►		1/1 11	Title ►	
Paid	Print/Type pre	parer's name	Preparer's signature	Date	Check if PTIN
Prepa	arer Seung Yoo		Miller for	07/30/25	self-employed P01341985
Use C		► Baker Tilly Adviso	ry Group, LP		Firm's EIN ▶ 39-0859910
-3 - -	July 		nnology Parkway, Campbell CA 95	5008-5071	Phone no. 408-558-7500
Send Fo			its) to: Department of the Treasury,		